EML4-ALK

EML4-ALK · Variant type: fusion · Fusion partner: EML4 (Eex14Aex20)

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Gilteritinib	98.3%	1.7%	88.97
2	Repotrectinib	97.7%	2.3%	84.21
3	Entrectinib	97.4%	2.6%	93.69
4	Sunitinib	88.5%	11.5%	91.73
5	Pralsetinib	81.5%	18.5%	93.43
6	Alpelisib	76.0%	23.9%	97.22
7	Pacritinib	50.6%	49.4%	88.64
8	Defactinib	36.4%	63.6%	92.68
9	Lazertinib	34.1%	65.9%	97.47
10	Tepotinib	30.8%	69.2%	99.75
11	Fedratinib	29.3%	70.7%	96.21
12	Darovasertib	26.2%	73.8%	96.99
13	Tenalisib	23.0%	77.0%	97.98
14	Neratinib	20.4%	79.6%	93.18
15	Upadacitinib	18.8%	81.2%	97.98
16	Abemaciclib	18.1%	81.9%	91.48
17	Vandetanib	18.1%	81.9%	95.74
18	Erlotinib	15.5%	84.5%	99.75
19	Palbociclib	15.2%	84.8%	98.75
20	Erdafitinib	12.7%	87.3%	95.71
21	Zanubrutinib	10.4%	89.6%	98.24
22	Pirtobrutinib	7.0%	93.0%	99.49
23	Inavolisib	6.8%	93.2%	100.00
24	Pexidartinib	6.3%	93.7%	99.49
25	Rabusertib	5.6%	94.4%	98.74

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Gilteritinib	98.3%	—	—
Repotrectinib	97.7%	—	—
Entrectinib	97.4%	—	—
Sunitinib	88.5%	—	—
Pralsetinib	81.5%	—	—
Alpelisib	76.0%	—	—
Pacritinib	50.6%	—	—
Defactinib	36.4%	—	—
Lazertinib	34.1%	—	—
Tepotinib	30.8%	—	—
Fedratinib	29.3%	—	—
Darovasertib	26.2%	—	—
Tenalisib	23.0%	—	—
Neratinib	20.4%	—	—
Upadacitinib	18.8%	—	—
Abemaciclib	18.1%	—	—
Vandetanib	18.1%	—	—
Erlotinib	15.5%	—	—
Palbociclib	15.2%	—	—
Erdafitinib	12.7%	—	—
Zanubrutinib	10.4%	—	—
Pirtobrutinib	7.0%	—	—
Inavolisib	6.8%	—	—
Pexidartinib	6.3%	—	—
Rabusertib	5.6%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.2ms